Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel, Apatinib, and S-1 in Gastric Cancer Conversion Therapy
NCT03718624Phase 2Unknown
- Sponsor
- Hebei Medical University
- Start
- Oct 2018
- Primary completion
- Oct 2019
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in gastric adenocarcinoma, sponsored by Hebei Medical University. Primary endpoints: R0-resection rate at 3 weeks and Conversion to negative rate at 3 weeks. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03718624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718624.